MA11.04 Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients

Management of non-small cell lung cancer (NSCLC) with EGFR or HER2 exon 20 mutations is an unmet medical need. Poziotinib, a potent, irreversible, tyrosine kinase inhibitor (TKI) of EGFR and HER2 exon 20 mutations, is being studied in a multi-cohort, multicenter, Phase 2 study (ZENITH20). Here, we present updated efficacy results across subgroups of NSCLC patients with EGFR and HER2 exon 20 insertion mutations. Topline results for 2nd line EGFR and HER2 cohorts (ZENITH20-1 and -2) were presented previously.